David Sebag: Delighted our letter about the PROSPECT rectal cancer trial
Quoting David Sebag-Montefiore, Director at Leeds Cancer Research Centre, on X/Twitter:
“Delighted our letter about the PROSPECT rectal cancer trial, with Andres Cervantes and Claus Rodel is published in The New England Journal of Medicine. We highlight important considerations in the trial findings from a global perspective and caution about its interpretation.
We strongly caution against the use of FOLFOX alone applied to the whole PROSPECT trial population. Also, FOLFOX and CRT represent significant over-treatment of a substantial proportion of the trial population (38% T3N0 disease with tumour >3mm from the mesolectal fascia).
The media description that FOLFOX allows patients to avoid the brutal side effects of radiotherapy is not balanced and misleading. The majority of late toxicity is due to radical surgery and precise modern RT reduces the additional impact of RT.”
For more information click here.
Source: David Sebag/Twitter.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023